Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 18 Issue 9, September 2019

‘Oncolytic virotherapy,’ inspired by the Review on p689.

Cover design: Susanne Harris.

Comment

  • One aspect of the ongoing debate about drug pricing is the added therapeutic benefit of new drugs compared with existing — and potentially cheaper — therapies. Here, we discuss the merits and pitfalls of proposals that are being discussed with regard to the role of regulatory agencies in establishing added therapeutic benefit.

    • Hans-Georg Eichler
    • Harald Enzmann
    • Guido Rasi
    Comment

    Advertisement

Top of page ⤴

News & Analysis

  • Recursion, Janssen, insitro and others are combining high-content phenotypic screening with machine learning to zoom in on emerging opportunities in target discovery, hit identification, toxicity testing and more.

    • Asher Mullard
    News
  • News in Brief

  • Biobusiness Briefs

  • An Audience With

    • Clinical trials can be big, cumbersome and unpredictable. Patients can be hard to recruit, and then their care has to be carefully coordinated through complex health-care systems, all while an ever-growing amount of data is collected and analysed. But if you could build a clinical trial operating system from the ground up, could you tame these beasts? Cardiologist Jessica Mega was running 10,000-plus patient trials at Harvard before jumping at the opportunity to take this task on at Google X in 2015. As chief medical and scientific officer at Verily, Alphabet’s resulting life sciences subsidiary, she now oversees a stable of projects that include immune profilers, wearable sensors and bioelectronic medicines. In May, Verily partnered with four large pharmaceutical firms to put its evolving clinical trial operating system to the test. She spoke with Asher Mullard about how her team is working to bring clinical trials to heel by optimizing patient recruitment and re-imagining health-care data.

      • Asher Mullard
      An Audience With
  • From the Analyst's Couch

Top of page ⤴

Research Highlights

Top of page ⤴

Reviews

  • Metabolic reprogramming alters immune cell activation, differentiation and function. Powell and colleagues discuss how to specifically modulate the activity of immune cells by altering their metabolism, suggesting a model of ‘cellular selectivity based on demand’, and highlight the opportunities to therapeutically target immunometabolism in cancer and autoimmune disorders.

    • Chirag H. Patel
    • Robert D. Leone
    • Jonathan D. Powell
    Review Article
  • Oncolytic viruses are currently seen as a potential therapeutic option for patients with cancer who do not respond to immune checkpoint inhibitors. This Review discusses the different therapeutic approaches to develop oncolytic viruses, delivery modalities and methods for assessing their biological activity.

    • Kevin Harrington
    • Daniel J. Freeman
    • Jean-Charles Soria
    Review Article
  • The complement system has a pivotal role in immunosurveillance and its dysregulation is involved in a variety of diseases. Here, Lambris and colleagues provide an overview of the pathological roles of the complement system in acute and chronic disorders, assessing recent developments in complement drug discovery, while highlighting the associated opportunities and challenges.

    • Dimitrios C. Mastellos
    • Daniel Ricklin
    • John D. Lambris
    Review Article
Top of page ⤴

Search

Quick links